Inflation Reduction Act Prescription Drug Savings Calculator

The Inflation Reduction Act is bringing real relief to millions of families, and it is critical the American people take advantage of these savings. Answer the questions below to see how much it might save you on health care costs.

Step 1 of 6

Are you enrolled in Medicare, or will you be enrolled in Medicare in 2025?(Required)

Yes

Optional Questions:

What state do you reside in?

To continue the fight to lower the price of prescription drugs and health care, protect coverage, and reduce health disparities, it is critical that people share their stories. If you would like to share your experience, please visit storytellercorps.com/share.

If you would like more information on health care and prescription drug savings, please provide your email address:

Other Communications By providing your email and checking the box below, you agree to receive emails from Protect Our Care or its affiliates or designees. You may unsubscribe at any time by following the instructions in those communications.
Age and Consent Requirements You are not permitted to upload or submit any material or information to this site if you are under 13 years of age. If you are at least 13 years of age and less than 18 years of age (or the age of legal majority in your jurisdiction of residence), you may only upload or submit material or information with the permission and supervision of your parent or legal guardian, who consents to these terms. By using this site to upload a submission and provide your email and phone, and checking the box below, you represent that: (i) you are at least 18 years of age (or the age of legal majority in your jurisdiction of residence); or (ii) if you are at least 13 years of age and less than 18 years of age, your parent or legal guardian has given you permission to use this site and make said submission, and has consented to these terms governing the site and submission.

Since you are or will soon be enrolled in Medicare, you stand to benefit from lower prescription drug costs. President Biden and Democrats in Congress have proposed expanding these savings to people with private insurance, too.

Currently, the Inflation Reduction Act lowers prescription drug costs for people on Medicare. In 2022, President Biden and Democrats in Congress passed legislation to lower prescription drug costs for people with Medicare. Republicans blocked them from applying these savings to people with private insurance, but President Biden and Democrats in Congress have proposed expanding these savings to people with private insurance.

You are likely to save money on out-of-pocket drug costs, thanks to the new prescription drug law passed by President Biden and Democrats in Congress. Starting in 2025, people with Medicare will pay no more than $2,000 per year on prescription drugs, and they will be able to arrange to spread out the cost of their co-pays over the course of the year.

Starting in 2025, people with Medicare will pay no more than $2,000 per year on prescription drugs. Thanks to the new prescription drug law passed by President Biden and Democrats in Congress, they will also be able to arrange to spread out the cost of their co-pays over the course of the year.

You are protected by a new $35 cap on monthly out-of-pocket insulin costs. Thanks to the new prescription drug law passed by President Biden and Democrats in Congress, the cost of insulin for people with Medicare is now capped at $35 per month per product.

Thanks to the new prescription drug law passed by President Biden and Democrats in Congress, the cost of insulin for people with Medicare is now capped at $35 per month per product.

You may qualify for free recommended vaccines. Thanks to the new prescription drug law passed by President Biden and Democrats in Congress, people with Medicare can now receive recommended vaccines for conditions including shingles, RSV, DTaP, seasonal flu, and COVID-19 for $0 out-of-pocket. With a single shot of Shingrix costing more than $180, seniors on Medicare Part D are saving over $400 on average.

You qualify for free recommended vaccines. Thanks to the new prescription drug law passed by President Biden and Democrats in Congress, starting in 2023, people with Medicare can now receive recommended vaccines for conditions including shingles, RSV, DTaP, seasonal flu, and COVID-19 for $0 out-of-pocket. With a single shot of Shingrix costing more than $180, seniors on Medicare Part D are saving over $400 on average on vaccinations in 2023.

In Alabama:

$35 monthly cap on insulin costs: Approximately 29,127 people on Medicare in Alabama are saving an average of $439 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 34,438 people on Medicare in Alabama are saving an average of $72 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 366,890 people on Medicare in Alabama will save an average of $360 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Alabama:

65,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
21,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
24,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
12,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
14,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
17,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
12,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Alaska:

$35 monthly cap on insulin costs: Approximately 1,026 people on Medicare in Alaska are saving an average of $598 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 3,985 people on Medicare in Alaska are saving an average of $54 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 30,520 people on Medicare in Alaska will save an average of $309 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Alaska:

6,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
2,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
2,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
1,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
1,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
1,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
1,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Arizona:

$35 monthly cap on insulin costs: Approximately 28,124 people on Medicare in Arizona are saving an average of $517 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 56,184 people on Medicare in Arizona are saving an average of $96 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 388,850 people on Medicare in Arizona will save an average of $379 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Arizona:

71,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
25,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
21,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
12,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
12,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
14,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
9,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Arkansas:

$35 monthly cap on insulin costs: Approximately 15,559 people on Medicare in Arkansas are saving an average of $540 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 16,586 people on Medicare in Arkansas are saving an average of $117 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 203,210 people on Medicare in Arkansas will save an average of $342 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Arkansas:

36,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
12,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
11,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
8,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
6,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
7,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
8,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In California:

$35 monthly cap on insulin costs: Approximately 108,164 people on Medicare in California are saving an average of $339 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 302,910 people on Medicare in California are saving an average of $66 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 2,180,530 people on Medicare in California will save an average of $296 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In California:

277,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
113,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
164,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
54,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
64,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
103,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
46,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
5,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
2,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
2,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Colorado:

$35 monthly cap on insulin costs: Approximately 16,085 people on Medicare in Colorado are saving an average of $515 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 46,441 people on Medicare in Colorado are saving an average of $94 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 220,050 people on Medicare in Colorado will save an average of $451 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Colorado:

43,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
21,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
15,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
6,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
5,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
6,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
4,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Connecticut:

$35 monthly cap on insulin costs: Approximately 11,444 people on Medicare in Connecticut are saving an average of $590 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 36,026 people on Medicare in Connecticut are saving an average of $79 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 255,900 people on Medicare in Connecticut will save an average of $368 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Connecticut:

49,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
19,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
19,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
7,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
8,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
13,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
7,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Delaware:

$35 monthly cap on insulin costs: Approximately 6,066 people on Medicare in Delaware are saving an average of $446 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 10,408 people on Medicare in Delaware are saving an average of $89 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 63,350 people on Medicare in Delaware will save an average of $449 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Delaware:

13,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
6,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
5,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
3,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
3,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
3,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
2,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In District of Columbia:

$35 monthly cap on insulin costs: Approximately 650 people on Medicare in District of Columbia are saving an average of $404 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 2,718 people on Medicare in District of Columbia are saving an average of $59 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 33,190 people on Medicare in District of Columbia will save an average of $184 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In District of Columbia:

4,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
1,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
2,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
1,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
Fewer than 1,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
1,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
1,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Florida:

$35 monthly cap on insulin costs: Approximately 90,181 people on Medicare in Florida are saving an average of $476 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 185,234 people on Medicare in Florida are saving an average of $95 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 1,479,230 people on Medicare in Florida will save an average of $401 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Florida:

282,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
105,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
83,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
58,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
47,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
62,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
49,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
3,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
2,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Georgia:

$35 monthly cap on insulin costs: Approximately 45,625 people on Medicare in Georgia are saving an average of $477 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 69,723 people on Medicare in Georgia are saving an average of $96 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 589,320 people on Medicare in Georgia will save an average of $395 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Georgia:

107,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
35,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
36,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
27,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
26,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
29,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
17,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Hawaii:

$35 monthly cap on insulin costs: Approximately 3,703 people on Medicare in Hawaii are saving an average of $389 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 18,236 people on Medicare in Hawaii are saving an average of $54 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 82,130 people on Medicare in Hawaii will save an average of $281 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Hawaii:

10,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
4,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
8,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
2,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
3,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
4,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
2,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Idaho:

$35 monthly cap on insulin costs: Approximately 7,927 people on Medicare in Idaho are saving an average of $606 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 14,284 people on Medicare in Idaho are saving an average of $129 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 82,160 people on Medicare in Idaho will save an average of $462 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Idaho:

19,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
6,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
5,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
4,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
3,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
2,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
1,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Illinois:

$35 monthly cap on insulin costs: Approximately 59,718 people on Medicare in Illinois are saving an average of $519 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 90,817 people on Medicare in Illinois are saving an average of $108 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 597,880 people on Medicare in Illinois will save an average of $433 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Illinois:

132,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
53,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
53,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
31,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
18,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
31,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
21,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Indiana:

$35 monthly cap on insulin costs: Approximately 42,310 people on Medicare in Indiana are saving an average of $541 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 63,321 people on Medicare in Indiana are saving an average of $95 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 385,650 people on Medicare in Indiana will save an average of $465 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Indiana:

81,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
30,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
30,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
19,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
14,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
18,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
14,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Iowa:

$35 monthly cap on insulin costs: Approximately 18,834 people on Medicare in Iowa are saving an average of $725 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 30,412 people on Medicare in Iowa are saving an average of $139 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 163,690 people on Medicare in Iowa will save an average of $525 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Iowa:

36,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
15,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
12,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
11,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
4,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
7,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
3,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Kansas:

$35 monthly cap on insulin costs: Approximately 15,657 people on Medicare in Kansas are saving an average of $650 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 23,836 people on Medicare in Kansas are saving an average of $126 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 129,630 people on Medicare in Kansas will save an average of $550 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Kansas:

29,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
12,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
10,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
10,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
5,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
6,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
3,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Kentucky:

$35 monthly cap on insulin costs: Approximately 27,797 people on Medicare in Kentucky are saving an average of $453 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 27,904 people on Medicare in Kentucky are saving an average of $89 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 333,560 people on Medicare in Kentucky will save an average of $359 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Kentucky:

60,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
23,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
23,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
16,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
15,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
20,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
11,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Louisiana:

$35 monthly cap on insulin costs: Approximately 22,071 people on Medicare in Louisiana are saving an average of $412 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 26,617 people on Medicare in Louisiana are saving an average of $89 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 327,110 people on Medicare in Louisiana will save an average of $320 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Louisiana:

55,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
19,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
23,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
13,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
11,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
16,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
13,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Maine:

$35 monthly cap on insulin costs: Approximately 5,976 people on Medicare in Maine are saving an average of $530 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 18,711 people on Medicare in Maine are saving an average of $87 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 126,850 people on Medicare in Maine will save an average of $298 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Maine:

21,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
6,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
7,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
4,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
2,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
4,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
1,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Maryland:

$35 monthly cap on insulin costs: Approximately 21,052 people on Medicare in Maryland are saving an average of $469 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 43,805 people on Medicare in Maryland are saving an average of $65 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 284,990 people on Medicare in Maryland will save an average of $388 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Maryland:

49,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
19,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
19,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
12,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
8,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
11,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
8,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Massachusetts:

$35 monthly cap on insulin costs: Approximately 26,287 people on Medicare in Massachusetts are saving an average of $504 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 77,011 people on Medicare in Massachusetts are saving an average of $64 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 481,730 people on Medicare in Massachusetts will save an average of $333 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Massachusetts:

89,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
26,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
30,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
16,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
8,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
16,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
8,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Michigan:

$35 monthly cap on insulin costs: Approximately 66,726 people on Medicare in Michigan are saving an average of $403 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 118,152 people on Medicare in Michigan are saving an average of $66 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 672,860 people on Medicare in Michigan will save an average of $356 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Michigan:

140,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
50,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
43,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
34,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
23,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
35,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
19,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
2,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Minnesota:

$35 monthly cap on insulin costs: Approximately 27,128 people on Medicare in Minnesota are saving an average of $672 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 62,744 people on Medicare in Minnesota are saving an average of $109 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 234,800 people on Medicare in Minnesota will save an average of $483 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Minnesota:

48,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
25,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
15,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
16,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
3,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
7,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
4,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Mississippi:

$35 monthly cap on insulin costs: Approximately 15,366 people on Medicare in Mississippi are saving an average of $543 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 10,871 people on Medicare in Mississippi are saving an average of $122 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 203,300 people on Medicare in Mississippi will save an average of $364 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Mississippi:

33,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
13,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
14,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
12,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
10,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
9,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
8,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Missouri:

$35 monthly cap on insulin costs: Approximately 34,881 people on Medicare in Missouri are saving an average of $523 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 51,929 people on Medicare in Missouri are saving an average of $90 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 348,280 people on Medicare in Missouri will save an average of $462 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Missouri:

75,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
27,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
26,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
18,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
14,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
15,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
11,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Montana:

$35 monthly cap on insulin costs: Approximately 4,835 people on Medicare in Montana are saving an average of $602 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 9,302 people on Medicare in Montana are saving an average of $144 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 54,010 people on Medicare in Montana will save an average of $461 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Montana:

10,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
4,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
3,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
3,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
1,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
2,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
1,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Nebraska:

$35 monthly cap on insulin costs: Approximately 9,716 people on Medicare in Nebraska are saving an average of $677 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 17,387 people on Medicare in Nebraska are saving an average of $139 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 88,600 people on Medicare in Nebraska will save an average of $630 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Nebraska:

20,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
10,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
7,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
5,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
3,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
3,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
3,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Nevada:

$35 monthly cap on insulin costs: Approximately 10,769 people on Medicare in Nevada are saving an average of $439 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 19,834 people on Medicare in Nevada are saving an average of $92 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 143,020 people on Medicare in Nevada will save an average of $434 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Nevada:

26,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
11,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
10,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
5,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
5,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
5,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
4,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In New Hampshire:

$35 monthly cap on insulin costs: Approximately 6,586 people on Medicare in New Hampshire are saving an average of $536 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 14,162 people on Medicare in New Hampshire are saving an average of $102 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 72,960 people on Medicare in New Hampshire will save an average of $490 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In New Hampshire:

16,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
5,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
4,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
2,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
1,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
2,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
1,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In New Jersey:

$35 monthly cap on insulin costs: Approximately 39,641 people on Medicare in New Jersey are saving an average of $511 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 64,179 people on Medicare in New Jersey are saving an average of $86 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 473,370 people on Medicare in New Jersey will save an average of $520 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In New Jersey:

99,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
39,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
34,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
15,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
22,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
33,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
16,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In New Mexico:

$35 monthly cap on insulin costs: Approximately 8,716 people on Medicare in New Mexico are saving an average of $443 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 17,826 people on Medicare in New Mexico are saving an average of $80 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 125,870 people on Medicare in New Mexico will save an average of $273 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In New Mexico:

15,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
10,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
6,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
5,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
3,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
5,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
2,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In New York:

$35 monthly cap on insulin costs: Approximately 75,601 people on Medicare in New York are saving an average of $483 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 135,188 people on Medicare in New York are saving an average of $65 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 1,145,400 people on Medicare in New York will save an average of $390 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In New York:

232,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
86,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
96,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
50,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
53,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
85,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
43,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
4,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
2,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
2,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In North Carolina:

$35 monthly cap on insulin costs: Approximately 56,921 people on Medicare in North Carolina are saving an average of $449 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 91,343 people on Medicare in North Carolina are saving an average of $83 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 662,600 people on Medicare in North Carolina will save an average of $406 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In North Carolina:

128,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
44,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
48,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
27,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
21,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
26,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
17,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
2,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In North Dakota:

$35 monthly cap on insulin costs: Approximately 4,527 people on Medicare in North Dakota are saving an average of $805 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 7,377 people on Medicare in North Dakota are saving an average of $148 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 33,050 people on Medicare in North Dakota will save an average of $506 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In North Dakota:

7,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
2,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
2,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
3,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
1,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
1,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
Fewer than 1,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Ohio:

$35 monthly cap on insulin costs: Approximately 72,854 people on Medicare in Ohio are saving an average of $502 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 112,871 people on Medicare in Ohio are saving an average of $88 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 687,430 people on Medicare in Ohio will save an average of $451 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Ohio:

155,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
57,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
47,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
33,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
27,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
39,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
21,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Oklahoma:

$35 monthly cap on insulin costs: Approximately 19,556 people on Medicare in Oklahoma are saving an average of $533 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 25,323 people on Medicare in Oklahoma are saving an average of $91 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 206,000 people on Medicare in Oklahoma will save an average of $452 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Oklahoma:

45,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
13,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
15,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
12,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
8,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
9,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
7,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Oregon:

$35 monthly cap on insulin costs: Approximately 17,915 people on Medicare in Oregon are saving an average of $591 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 44,796 people on Medicare in Oregon are saving an average of $97 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 224,100 people on Medicare in Oregon will save an average of $388 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Oregon:

46,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
15,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
14,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
7,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
3,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
4,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
5,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Pennsylvania:

$35 monthly cap on insulin costs: Approximately 80,197 people on Medicare in Pennsylvania are saving an average of $543 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 145,920 people on Medicare in Pennsylvania are saving an average of $72 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 829,770 people on Medicare in Pennsylvania will save an average of $467 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Pennsylvania:

187,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
67,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
71,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
45,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
21,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
37,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
23,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
2,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Rhode Island:

$35 monthly cap on insulin costs: Approximately 4,678 people on Medicare in Rhode Island are saving an average of $485 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 10,580 people on Medicare in Rhode Island are saving an average of $82 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 68,120 people on Medicare in Rhode Island will save an average of $340 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Rhode Island:

14,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
5,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
5,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
2,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
1,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
2,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
1,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In South Carolina:

$35 monthly cap on insulin costs: Approximately 31,235 people on Medicare in South Carolina are saving an average of $477 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 47,167 people on Medicare in South Carolina are saving an average of $88 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 334,960 people on Medicare in South Carolina will save an average of $435 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In South Carolina:

67,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
21,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
23,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
14,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
16,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
17,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
12,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In South Dakota:

$35 monthly cap on insulin costs: Approximately 4,568 people on Medicare in South Dakota are saving an average of $725 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 8,698 people on Medicare in South Dakota are saving an average of $165 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 39,710 people on Medicare in South Dakota will save an average of $587 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In South Dakota:

9,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
4,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
3,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
3,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
1,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
1,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
1,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Tennessee:

$35 monthly cap on insulin costs: Approximately 39,562 people on Medicare in Tennessee are saving an average of $494 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 45,424 people on Medicare in Tennessee are saving an average of $95 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 459,280 people on Medicare in Tennessee will save an average of $417 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Tennessee:

85,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
30,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
28,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
19,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
16,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
18,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
13,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Texas:

$35 monthly cap on insulin costs: Approximately 114,242 people on Medicare in Texas are saving an average of $441 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 156,846 people on Medicare in Texas are saving an average of $87 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 1,323,430 people on Medicare in Texas will save an average of $400 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Texas:

221,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
86,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
99,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
48,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
58,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
70,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
35,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
4,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Utah:

$35 monthly cap on insulin costs: Approximately 11,393 people on Medicare in Utah are saving an average of $624 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 18,917 people on Medicare in Utah are saving an average of $109 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 95,950 people on Medicare in Utah will save an average of $491 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Utah:

22,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
8,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
7,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
5,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
3,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
3,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
1,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Vermont:

$35 monthly cap on insulin costs: Approximately 3,118 people on Medicare in Vermont are saving an average of $691 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 7,795 people on Medicare in Vermont are saving an average of $110 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 44,030 people on Medicare in Vermont will save an average of $492 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Vermont:

9,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
3,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
3,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
2,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
1,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
1,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
1,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Virginia:

$35 monthly cap on insulin costs: Approximately 36,461 people on Medicare in Virginia are saving an average of $510 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 57,990 people on Medicare in Virginia are saving an average of $101 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 390,400 people on Medicare in Virginia will save an average of $441 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Virginia:

81,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
26,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
26,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
15,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
13,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
20,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
11,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Washington:

$35 monthly cap on insulin costs: Approximately 28,063 people on Medicare in Washington are saving an average of $603 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 79,980 people on Medicare in Washington are saving an average of $87 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 344,470 people on Medicare in Washington will save an average of $413 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Washington:

58,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
27,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
26,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
11,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
6,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
9,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
6,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In West Virginia:

$35 monthly cap on insulin costs: Approximately 12,656 people on Medicare in West Virginia are saving an average of $451 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 11,661 people on Medicare in West Virginia are saving an average of $76 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 140,540 people on Medicare in West Virginia will save an average of $346 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In West Virginia:

27,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
10,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
10,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
10,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
5,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
9,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
5,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Wisconsin:

$35 monthly cap on insulin costs: Approximately 31,935 people on Medicare in Wisconsin are saving an average of $628 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 70,566 people on Medicare in Wisconsin are saving an average of $91 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 298,750 people on Medicare in Wisconsin will save an average of $475 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Wisconsin:

68,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
23,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
22,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
15,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
6,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
11,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
6,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.

In Wyoming:

$35 monthly cap on insulin costs: Approximately 2,469 people on Medicare in Wyoming are saving an average of $647 per year on out-of-pocket insulin costs.
Free Recommended Vaccinations: Approximately 3,867 people on Medicare in Wyoming are saving an average of $147 per year on out-of-pocket vaccine costs.
$2,000 Cap On Out-Of-Pocket Drug Costs: Starting in 2025, approximately 21,920 people on Medicare in Wyoming will save an average of $608 per year on out-of-pocket prescription drug costs.
Lower Prices Negotiated By Medicare: Starting in 2026, lower prices will take effect for the first ten drugs with lower prices negotiated by Medicare. In Wyoming:

6,000 people take Eliquis, and its net price is projected to decrease by $1,476 annually.
2,000 people take Xarelto, and its net price is projected to decrease by $1,416 annually.
1,000 people take Jardiance, and its net price is projected to decrease by $1,824 annually.
1,000 people take NovoLog, and its net price is projected to decrease by $360 annually.
1,000 people take Farxiga, and its net price is projected to decrease by $1,992 annually.
1,000 people take Januvia, and its net price is projected to decrease by $1,656 annually.
Fewer than 1,000 people take Entresto, and its net price is projected to decrease by $3,444 annually.
Fewer than 1,000 people take Enbrel, and its net price is projected to decrease by $30,912 annually.
Fewer than 1,000 people take Imbruvica, and its net price is projected to decrease by $78,576 annually.
Fewer than 1,000 people take Stelara, and its net price is projected to decrease by $13,836 annually.